180 related articles for article (PubMed ID: 19663564)
1. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity.
Hu B; Yang H; Dai B; Tai A; Wang P
Hum Gene Ther; 2009 Dec; 20(12):1652-64. PubMed ID: 19663564
[TBL] [Abstract][Full Text] [Related]
2. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
3. Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity.
Hu B; Dai B; Wang P
Vaccine; 2010 Sep; 28(41):6675-83. PubMed ID: 20709004
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
5. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
6. Engineered lentivector targeting of dendritic cells for in vivo immunization.
Yang L; Yang H; Rideout K; Cho T; Joo KI; Ziegler L; Elliot A; Walls A; Yu D; Baltimore D; Wang P
Nat Biotechnol; 2008 Mar; 26(3):326-34. PubMed ID: 18297056
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.
Uhlig KM; Schülke S; Scheuplein VA; Malczyk AH; Reusch J; Kugelmann S; Muth A; Koch V; Hutzler S; Bodmer BS; Schambach A; Buchholz CJ; Waibler Z; Scheurer S; Mühlebach MD
J Virol; 2015 Sep; 89(17):9044-60. PubMed ID: 26085166
[TBL] [Abstract][Full Text] [Related]
8. Pseudotyping lentiviral vectors with lymphocytic choriomeningitis virus glycoproteins for transduction of dendritic cells and in vivo immunization.
Zhang C; Hu B; Xiao L; Liu Y; Wang P
Hum Gene Ther Methods; 2014 Dec; 25(6):328-38. PubMed ID: 25416034
[TBL] [Abstract][Full Text] [Related]
9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
10. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
[TBL] [Abstract][Full Text] [Related]
11. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
[TBL] [Abstract][Full Text] [Related]
12. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
He Y; Zhang J; Mi Z; Robbins P; Falo LD
J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
[TBL] [Abstract][Full Text] [Related]
13. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
Dullaers M; Thielemans K
J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Nonintegrating Lentiviruses as Safe Vectors for Noninvasive Reporter-Based Molecular Imaging of Multipotent Mesenchymal Stem Cells.
Hamilton AM; Foster PJ; Ronald JA
Hum Gene Ther; 2018 Oct; 29(10):1213-1225. PubMed ID: 30101620
[TBL] [Abstract][Full Text] [Related]
15. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
16. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.
Villegas-Mendez A; Garin MI; Pineda-Molina E; Veratti E; Bueren JA; Fender P; Lenormand JL
Mol Ther; 2010 May; 18(5):1046-53. PubMed ID: 20179681
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
Cervantes-Barragan L; Züst R; Maier R; Sierro S; Janda J; Levy F; Speiser D; Romero P; Rohrlich PS; Ludewig B; Thiel V
mBio; 2010 Sep; 1(4):. PubMed ID: 20844609
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
Shibagaki N; Udey MC
J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
[TBL] [Abstract][Full Text] [Related]
19. The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross-presenting dendritic cells.
Henning P; Gustafsson T; Flach CF; Hua YJ; Strömbeck A; Holmgren J; Lindholm L; Yrlid U
Eur J Immunol; 2011 Aug; 41(8):2185-96. PubMed ID: 21538977
[TBL] [Abstract][Full Text] [Related]
20. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
